137 related articles for article (PubMed ID: 32903213)
61. Urinary metabolomic signature of esophageal cancer and Barrett's esophagus.
Davis VW; Schiller DE; Eurich D; Sawyer MB
World J Surg Oncol; 2012 Dec; 10():271. PubMed ID: 23241138
[TBL] [Abstract][Full Text] [Related]
62. Helicobacter pylori induces caudal-type homeobox protein 2 and cyclooxygenase 2 expression by modulating microRNAs in esophageal epithelial cells.
Teng G; Dai Y; Chu Y; Li J; Zhang H; Wu T; Shuai X; Wang W
Cancer Sci; 2018 Feb; 109(2):297-307. PubMed ID: 29215765
[TBL] [Abstract][Full Text] [Related]
63. Alteration of the esophageal microbiota in Barrett's esophagus and esophageal adenocarcinoma.
Lv J; Guo L; Liu JJ; Zhao HP; Zhang J; Wang JH
World J Gastroenterol; 2019 May; 25(18):2149-2161. PubMed ID: 31143067
[TBL] [Abstract][Full Text] [Related]
64. Serum 25-Hydroxyvitamin D Levels and the Risk of Dysplasia and Esophageal Adenocarcinoma in Patients with Barrett's Esophagus.
Thota PN; Kistangari G; Singh P; Cummings L; Hajifathalian K; Lopez R; Sanaka MR
Dig Dis Sci; 2016 Jan; 61(1):247-54. PubMed ID: 26233550
[TBL] [Abstract][Full Text] [Related]
65. Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma.
Samuels TL; Altman KW; Gould JC; Kindel T; Bosler M; MacKinnon A; Hagen CE; Johnston N
Laryngoscope; 2019 Dec; 129(12):2687-2695. PubMed ID: 31046139
[TBL] [Abstract][Full Text] [Related]
66. [Screening for adenocarcinoma in Barrett's esophagus: yes or no, when and how?].
Sostres C; Lacarta P; Lanas A
Gastroenterol Hepatol; 2013 Oct; 36(8):520-6. PubMed ID: 23453559
[TBL] [Abstract][Full Text] [Related]
67. microRNAs: Key regulators of chemotherapy response and metastatic potential via complex control of target pathways in esophageal adenocarcinoma.
Matuszcak C; Lindner K; Eichelmann AK; Hussey DJ; Haier J; Hummel R
Surg Oncol; 2018 Sep; 27(3):392-401. PubMed ID: 30217293
[TBL] [Abstract][Full Text] [Related]
68. Gene Expression in Barrett's Esophagus Cell Lines Resemble Esophageal Squamous Cell Carcinoma Instead of Esophageal Adenocarcinoma.
Panda A; Bhanot G; Ganesan S; Bajpai M
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885081
[TBL] [Abstract][Full Text] [Related]
69. Targeting the COX1/2-Driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma development.
Zhang T; Wang Q; Ma WY; Wang K; Chang X; Johnson ML; Bai R; Bode AM; Foster NR; Falk GW; Limburg PJ; Iyer PG; Dong Z
EBioMedicine; 2019 Nov; 49():145-156. PubMed ID: 31707149
[TBL] [Abstract][Full Text] [Related]
70. Evaluation of Mutational Testing of Preneoplastic Barrett's Mucosa by Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Endoscopic Samples for Detection of Concurrent Dysplasia and Adenocarcinoma in Barrett's Esophagus.
Del Portillo A; Lagana SM; Yao Y; Uehara T; Jhala N; Ganguly T; Nagy P; Gutierrez J; Luna A; Abrams J; Liu Y; Brand R; Sepulveda JL; Falk GW; Sepulveda AR
J Mol Diagn; 2015 Jul; 17(4):412-9. PubMed ID: 26068095
[TBL] [Abstract][Full Text] [Related]
71. Serum outperforms plasma in small extracellular vesicle microRNA biomarker studies of adenocarcinoma of the esophagus.
Chiam K; Mayne GC; Wang T; Watson DI; Irvine TS; Bright T; Smith LT; Ball IA; Bowen JM; Keefe DM; Thompson SK; Hussey DJ
World J Gastroenterol; 2020 May; 26(20):2570-2583. PubMed ID: 32523312
[TBL] [Abstract][Full Text] [Related]
72. Hypoxic BMSC-derived exosomal miRNAs promote metastasis of lung cancer cells via STAT3-induced EMT.
Zhang X; Sai B; Wang F; Wang L; Wang Y; Zheng L; Li G; Tang J; Xiang J
Mol Cancer; 2019 Mar; 18(1):40. PubMed ID: 30866952
[TBL] [Abstract][Full Text] [Related]
73. FABP1 and Hepar expression levels in Barrett's esophagus and associated neoplasia in an Asian population.
Srivastava S; Kern F; Sharma N; McKeon F; Xian W; Yeoh KG; Ho KY; Teh M
Dig Liver Dis; 2017 Oct; 49(10):1104-1109. PubMed ID: 28807490
[TBL] [Abstract][Full Text] [Related]
74. Expression of the putative stem cell marker Musashi-1 in Barrett's esophagus and esophageal adenocarcinoma.
Bobryshev YV; Freeman AK; Botelho NK; Tran D; Levert-Mignon AJ; Lord RV
Dis Esophagus; 2010 Sep; 23(7):580-9. PubMed ID: 20459440
[TBL] [Abstract][Full Text] [Related]
75. Minichromosomal Maintenance Component Complex 5 (MCM5) as a Marker of Barrett's Esophagus-Related Neoplasia: A Feasibility Study.
Everson M; Magee C; Alzoubaidi D; Brogden S; Graham D; Lovat LB; Novelli M; Haidry R
Dig Dis Sci; 2019 Oct; 64(10):2815-2822. PubMed ID: 30982210
[TBL] [Abstract][Full Text] [Related]
76. Differential Expression of NEK Kinase Family Members in Esophageal Adenocarcinoma and Barrett's Esophagus.
Chen L; Ballout F; Lu H; Hu T; Zhu S; Chen Z; Peng D
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835513
[TBL] [Abstract][Full Text] [Related]
77. MicroRNAs in Esophageal Adenocarcinoma: Functional Significance and Potential for the Development of New Molecular Disease Markers.
Bobryshev YV; Orekhov AN; Chistiakov DA
Curr Pharm Des; 2015; 21(23):3402-16. PubMed ID: 25758856
[TBL] [Abstract][Full Text] [Related]
78. The diagnosis and management of Barrett's esophagus.
DeMeester SR; DeMeester TR
Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
[TBL] [Abstract][Full Text] [Related]
79. Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.
Sharaiha RZ; Freedberg DE; Abrams JA; Wang YC
Dig Dis Sci; 2014 Jun; 59(6):1222-30. PubMed ID: 24795040
[TBL] [Abstract][Full Text] [Related]
80. Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas.
Corley DA; Mehtani K; Quesenberry C; Zhao W; de Boer J; Weiss NS
Gastroenterology; 2013 Aug; 145(2):312-9.e1. PubMed ID: 23673354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
